Plasma Derived Therapy Market Analysis

Product (Immunoglobulins, Coagulation Factors, Albumin)

Immunoglobulins segment is poised to hold over 49% plasma derived therapy market share by the end of 2036. The segment growth can be attributed to the people having an interest in this plasma-derived therapy due to the increasing demand for it. A large number of people are suffering from chronic diseases that are cured by this immunoglobulin plasma-derived component has been a notable reason for the market’s growth.

 Also, the increased research and development efforts by the major market players involved in the industry further drive the growth of the market. According to recent research, success rates of immune thrombocytopenia (ITP) vary from person to person but in adults with acute ITP, response rates of immunoglobulin are around 60%.

Application (Hemophilia, Primary Immunodeficiency Diseases, Idiopathic /Immune Thrombocytopenic Purpura (ITP)

By 2036, hemophilia segment is expected to hold more than 54% plasma derived therapy market share. The segment growth is associated with the surging number of cases distressed from hemophilia across the world, majorly in underdeveloped and developed countries. According to the Hemophilia Foundation Australia, this disease is reported to occur in 1 in 6,000-10,000 males internationally where around 1 in 6,000 males have hemophilia A and 1 in 25,000-30,000 males has hemophilia B.

Our in-depth analysis of the global market includes the following segments: